ABIVAX Société Anonyme (LON:0RA9)

Market Cap	4.03B
Revenue (ttm)	8.86M
Net Income (ttm)	-155.39M
Shares Out	n/a
EPS (ttm)	-2.46
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,425
Average Volume	7,592
Open	60.70
Previous Close	60.10
Day's Range	60.10 - 62.60
52-Week Range	4.57 - 62.60
Beta	1.53
RSI	91.90
Earnings Date	Aug 11, 2025

About R1 RCM

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2013
• Employees: 69
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0RA9

Financial Performance

In 2024, ABIVAX Société Anonyme's revenue was 10.79 million, an increase of 135.94% compared to the previous year's 4.57 million. Losses were -176.24 million, 19.3% more than in 2023.